Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
Comment by Longholder99on Aug 23, 2024 6:40pm

RE:RE:RE:In the pipeline...

I agree Mikee.  If BTD comes through, Theralase will only exist as a subsidiary of a big Pharm but I suspect they will be bought after a series of multi million share buys in a race to see who ...more  
215
Discussion
Comment by chry200030on Aug 23, 2024 6:11pm

RE:RE:RE:In the pipeline...

It's one game. They are playing a lot of games...ie.. a lot of irons in the fire. It's all about whether they can finance their game or make a deal somewhere. . 
96
Discussion
Comment by DeathXray33on Aug 23, 2024 5:22pm

RE:RE:Very interesting---

That's my thinking also. That would be a great bargain though; It's worth a lot more. In the end, it'll be fair for everyone.
102
Discussion
Comment by Mikee3003on Aug 23, 2024 5:14pm

RE:RE:In the pipeline...

In the pipeline....lol! Get real....bladder is the end game for Theralase. We are either successful with bladder or we go bankrupt. All these woopdie doo news releases of late mean squat and the ...more  
196
Discussion
Comment by Gooseybearon Aug 23, 2024 4:27pm

RE:RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

If you think that the FDA regulators don't talk to their international counterparts you are sorely mistaken.  As a longtime holder of TLTFF, I want them to succeed but don't be blinded by ...more  
168
Discussion
Comment by 2b7f6fabon Aug 23, 2024 4:16pm

RE:Very interesting---

With the latest news release of activation using Metformin, if true, I'm tripling my minimum target buyout price to $10 billion.  Think of how cheap and simple it would be to run the bladder ...more  
191
Discussion
Comment by DJDawgon Aug 23, 2024 4:13pm

RE:RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

I think that the FDA is more likely to be biased against easy BTD for newer technologies. I also think that they are more likely to approve if the application comes in with the consultative support of ...more  
150
Discussion
Comment by Alamir1111on Aug 23, 2024 3:34pm

RE: HAS GLP TOXICOLOGY ANALYSIS OF RUTHERRIN NOT BEEN DONE

Rutherrin was mentioned how many years ago ??
70
Discussion
Comment by Longholder99on Aug 23, 2024 3:26pm

RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

The FDA granting approval or not based in trust vs data on an oncology drug.  Hokding back now because of some half baked whiney complaint of many years ago for cold laser therapy claims ...more  
163
Discussion
Comment by Gooseybearon Aug 23, 2024 2:46pm

RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

TLT is having to jump through additional regulatory hoops due to the checkered past of the CEO with the regulators. I've worked with regulators in the US so I've seen that trust with them ...more  
150
Discussion
Post by Tarbabyon Aug 23, 2024 2:44pm

HAS GLP TOXICOLOGY ANALYSIS OF RUTHERRIN NOT BEEN DONE

ROGER  has several times stated this is PENDING...Shouldnt toxicology analysis be JOB1 with any newly developed drug.. Dont they need Health Canada approval of Rutherrin before they can do any ...more  
188
Discussion
Comment by Gooseybearon Aug 23, 2024 2:41pm

RE:Very interesting---

I've had NIMBC and Keytruda was not even considered as a treatment due to the significant side effects vs. BCG.
82
Discussion
Comment by Legit62on Aug 23, 2024 1:20pm

RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

Great point DJDawg,have to agree with you on this one, the party bus has slowed but will pick up steam shortly,lets hope we bring in the 10 million people have been talking about,we need the funds now
110
Discussion
Post by Impalamanon Aug 23, 2024 12:47pm

Very interesting---

Mercks--Keytruda 's patent will run out in 2028----We should have full approval of  Rudivar by 2026-----Huuummmmm very interesting  ---Hang on to your TLT  guy's
166
Discussion
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250